Treatment of cushing's syndrome: An endocrine society clinical practice guideline

Lynnette K. Nieman, Beverly M K Biller, James W. Findling, Mohammad H Murad, John Newell-Price, Martin O. Savage, Antoine Tabarin

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Objective: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. Participants: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. Evidence: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.

Original languageEnglish (US)
Pages (from-to)2807-2831
Number of pages25
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Cushing Syndrome
Advisory Committees
Practice Guidelines
Endocrinology
Teleconferencing
Radiotherapy
Antihypertensive Agents
Hydrocortisone
Comorbidity
Tumors
Consensus
Guidelines
Committee Membership
Group Processes
Communication
Adrenalectomy
Postal Service
Therapeutics
Mortality
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015). Treatment of cushing's syndrome: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 100(8), 2807-2831. https://doi.org/10.1210/jc.2015-1818

Treatment of cushing's syndrome : An endocrine society clinical practice guideline. / Nieman, Lynnette K.; Biller, Beverly M K; Findling, James W.; Murad, Mohammad H; Newell-Price, John; Savage, Martin O.; Tabarin, Antoine.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 8, 01.08.2015, p. 2807-2831.

Research output: Contribution to journalArticle

Nieman, LK, Biller, BMK, Findling, JW, Murad, MH, Newell-Price, J, Savage, MO & Tabarin, A 2015, 'Treatment of cushing's syndrome: An endocrine society clinical practice guideline', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 8, pp. 2807-2831. https://doi.org/10.1210/jc.2015-1818
Nieman, Lynnette K. ; Biller, Beverly M K ; Findling, James W. ; Murad, Mohammad H ; Newell-Price, John ; Savage, Martin O. ; Tabarin, Antoine. / Treatment of cushing's syndrome : An endocrine society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 8. pp. 2807-2831.
@article{caf2b465f79f4fa0a787f090d61f57a9,
title = "Treatment of cushing's syndrome: An endocrine society clinical practice guideline",
abstract = "Objective: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. Participants: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. Evidence: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.",
author = "Nieman, {Lynnette K.} and Biller, {Beverly M K} and Findling, {James W.} and Murad, {Mohammad H} and John Newell-Price and Savage, {Martin O.} and Antoine Tabarin",
year = "2015",
month = "8",
day = "1",
doi = "10.1210/jc.2015-1818",
language = "English (US)",
volume = "100",
pages = "2807--2831",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Treatment of cushing's syndrome

T2 - An endocrine society clinical practice guideline

AU - Nieman, Lynnette K.

AU - Biller, Beverly M K

AU - Findling, James W.

AU - Murad, Mohammad H

AU - Newell-Price, John

AU - Savage, Martin O.

AU - Tabarin, Antoine

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. Participants: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. Evidence: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.

AB - Objective: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. Participants: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. Evidence: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.

UR - http://www.scopus.com/inward/record.url?scp=84939154059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939154059&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-1818

DO - 10.1210/jc.2015-1818

M3 - Article

C2 - 26222757

AN - SCOPUS:84939154059

VL - 100

SP - 2807

EP - 2831

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -